Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (12052)	12/4/1997 12:02:00 PM
From: Alper H.YUKSEL	Read Replies (1) \| Respond to of 32384

Peter (or anybody on the thread), Is it possible to differentiate between 'real buying' and MM's exchanging shares to lure in buyers, thus getting rid of 'excess inventory' ? TIA

To: Proton who wrote (12052)	12/4/1997 12:12:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

PP, Looks like we're surrounded by news :-). The diabetes news, which I assume is "all" is behind us, but the Business Week (lol) article has been "leaked" and is now "in front of us". Actually, all I know about the 3 articles that I had mentioned awhile ago, is the fact that I haven't been able to find them, so I'm pretty sure they are not out yet. The presentaion at Robertson Stephens was Tuesday, but LGND presents at the retail conference featuring Jim McCamant and Michael Murphy in the middle of this month. As far as anticipation of events is concerned, there is clearly much more "in front of us". Pivotal Phase III results for Panretin is still slated for this month as far as I know, and of course diabetes treatments are front and center because of the Rezulin problems. I'll won't add more "rumors" on upcomong events, but I can mention that I do have first hand knowledge on interviews for patient's reactions to the Rezulin situation (which really should not come as a surprise to anyone). Since ALRI is now gone and the LLY deal is a done deal, the way has been paved for an announcement of the LLY drug as well as IND filing for LGND1268 and US diabetes trials for Targretin.